6/27/2025

The global sickle cell disease treatment market is poised for significant growth, driven by the increasing prevalence of the disease and the demand for effective treatments. North America, led by the U.S., dominates the market with strong healthcare infrastructure, government support, and research innovations. In Asia-Pacific, countries like China and India are experiencing rapid market growth due to rising healthcare expenditure and increased awareness. Europe also contributes significantly, su

Source: Yahoo

6/27/2025

Bristol Myers Squibb announces that the US FDA has approved updated labeling for its two CAR-T cell therapies, Breyanzi for B-cell lymphoma and other lymphomas, and Abecma for multiple myeloma.This...

Source: Finnhub

6/27/2025

PRINCETON, N.J., June 27, 2025--U.S. FDA Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels

Source: Yahoo

6/27/2025

Bristol Myers Squibb announced that the U.S. Food and Drug Administration has approved label updates for both of its CAR T cell therapies, Breyanzi®? for the treatment of large B cell lymphoma and...

Source: Finnhub

6/26/2025

Incyte stock popped Thursday after the company's board appointed Bill Meury as its new CEO, replacing Herve Hoppenot, who is retiring.

Source: Yahoo

6/26/2025

Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry nears.

Source: Yahoo

6/26/2025

Bill Meury, who shepherded Karuna and Anthos to multibillion-dollar buyouts, will take over Incyte, a successful drug developer now at a crossroads.

Source: Yahoo

6/26/2025

Incyte Names Bill Meury CEO as Herve Hoppenot Retires

Source: MarketWatch

6/25/2025

Bristol-Myers Squibb Company (NYSE:BMY) ranks among the top stocks for an early retirement portfolio. On June 12, Cantor Fitzgerald maintained its price target of $55 and its rating of Neutral for Bristol-Myers Squibb Company (NYSE:BMY). The company’s Cobenfy’s ADEPT-2 top-line data in Alzheimer’s Disease Psychosis is anticipated in 2025, possibly as early as the second […]

Source: Yahoo

6/25/2025

BMY depends on Reblozyl, Opdualag and Breyanzi to offset revenue hits from generics and Medicare Part D impacts.

Source: Yahoo

3/19/2025

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Source: Yahoo

6/24/2025

Bristol-Myers Squibb Company (NYSE:BMY) is the third biopharmaceutical company on the list of the 10 undervalued blue chip stocks analysts recommend for smart investing. On June 17, the company announced a quarterly cash dividend of $0.60 per share on its common stock. This is the 95th consecutive year that the conglomerate has paid a dividend. […]

Source: Yahoo

6/24/2025

Health care stocks rose late Tuesday afternoon, with the NYSE Health Care Index adding 1.3% and the

Source: Yahoo

6/24/2025

Cigna Group (CI) filed a lawsuit against Bristol Myers Squibb (BMY), accusing the pharmaceutical gia

Source: Yahoo

6/24/2025

EXEL jumps 7.4% as STELLAR-303 trial hits key survival goal in colorectal cancer, boosting hopes for an approval of zanzalintinib.

Source: Yahoo

6/24/2025

Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Source: Yahoo

6/24/2025

Source: SeekingAlpha

6/24/2025

Discover 2 undervalued monthly dividend stocks with strong growth potential, high credit ratings, and reliable yields.

Source: SeekingAlpha

6/24/2025

Buying Dividend Aristocrats at bargain prices can be a winning investment strategy. Read about two such stocks that are undervalued vs. historical norms.

Source: SeekingAlpha

6/23/2025

Source: SeekingAlpha